KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Recursion Pharmaceuticals (RXRX) Change in Acquisitions & Divestments (2021 - 2023)

Recursion Pharmaceuticals (RXRX) has disclosed Change in Acquisitions & Divestments for 3 consecutive years, with $480000.0 as the latest value for Q3 2023.

  • For the quarter ending Q3 2023, Change in Acquisitions & Divestments fell 99.22% year-over-year to $480000.0, compared with a TTM value of $480000.0 through Dec 2024, changed 0.0%, and an annual FY2023 reading of $480000.0, down 99.79% over the prior year.
  • Change in Acquisitions & Divestments was $480000.0 for Q3 2023 at Recursion Pharmaceuticals, down from $61.5 million in the prior quarter.
  • Across five years, Change in Acquisitions & Divestments topped out at $147.6 million in Q1 2022 and bottomed at $480000.0 in Q3 2023.
  • Average Change in Acquisitions & Divestments over 3 years is $60.1 million, with a median of $61.5 million recorded in 2022.
  • Peak annual rise in Change in Acquisitions & Divestments hit 99.22% in 2023, while the deepest fall reached 99.22% in 2023.
  • Year by year, Change in Acquisitions & Divestments stood at $69.2 million in 2021, then dropped by 11.05% to $61.5 million in 2022, then plummeted by 99.22% to $480000.0 in 2023.
  • Business Quant data shows Change in Acquisitions & Divestments for RXRX at $480000.0 in Q3 2023, $61.5 million in Q3 2022, and $21.4 million in Q2 2022.